Sydney Montesi
Clinical Investigator, Associate Professor of Medicine, Pulmonary Massachusetts General Hospital and Harvard Medical School
Dr. Sydney Montesi is a leading clinician-scientist specializing in interstitial lung diseases and pulmonary fibrosis, with dual expertise in patient care and translational research. She serves as Associate Professor of Medicine at Harvard Medical School and Associate Physician in Pulmonary and Critical Care Medicine at Massachusetts General Hospital, where she bridges groundbreaking research with clinical innovation.
Board-certified in Pulmonary Disease, Critical Care Medicine, and Internal Medicine, Dr. Montesi completed her MD at the University of Rochester, followed by residency and fellowship training at Massachusetts General Hospital and the Harvard Combined Program. Her work focuses on elucidating mechanisms of fibrogenesis and improving outcomes for patients with idiopathic pulmonary fibrosis (IPF) and related disorders. As a Principal Investigator at the Mass General Research Institute, she leads studies spanning biomarkers, prognostic tools, and novel therapeutic strategies, with a keen interest in the intersection of molecular imaging and fibrosis progression.
A respected voice in ILD, Dr. Montesi’s research has advanced understanding of disease severity, patient-centered outcomes, and antifibrotic interventions, making her a vital contributor to the future of pulmonary fibrosis therapeutics.
Seminars
Forced Vital Capacity remains the anchor endpoint for pulmonary fibrosis trials and the filed remains split on torn on its value. What’s more the field is evolving to capture a more complete picture of disease progression and therapeutic impact. This panel will dig into FVC and secondary endpoints, the emerging role of quantitative HRCT and other imaging biomarkers, the evidence required for regulatory acceptance, standardization across providers, and the integration of multi-modal endpoints into trial design, all to ensure you leave with a clear understanding of how to design trials that balance traditional FVC measurements with innovative endpoints, enabling robust efficacy assessment, regulatory alignment, and differentiation in an increasingly complex ILD landscape.
- The continued relevance of FVC as a surrogate for disease progression and mortality in IPF and PPF
- How secondary endpoints can complement FVC to reveal meaningful changes in symptoms, quality of life, and disease biology
- Advances in quantitative imaging, including AI-driven HRCT, and the pathway toward regulatory qualification
- Strategies for integrating multi-modal endpoints into trial design without overcomplicating study execution
- Practical considerations for trial sponsors: standardization, subgroup analysis, and managing background therapy
